Anidulafungin

Drugs in R and D

Volumn 4, Issue 3, 2003, Pages 167-173

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; AMPHOTERICIN B; ANIDULAFUNGIN; CILOFUNGIN; CORTISONE ACETATE; CYCLOSPORIN; DEXAMETHASONE; FLUCONAZOLE; FLUCYTOSINE; GLUCOCORTICOID; ITRACONAZOLE; MICONAZOLE; TRIAMCINOLONE; VER 02; ANTIFUNGAL AGENT; CYCLOPEPTIDE; NEW DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MYCOSIS; NONHUMAN; PHLEBITIS; PNEUMOCYSTOSIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; ANIMAL; CANDIDA; DRUG EFFECT; MICROBIOLOGY; REVIEW; SACCHAROMYCES CEREVISIAE;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; CANDIDA; CANDIDIASIS; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; PEPTIDES, CYCLIC; SACCHAROMYCES CEREVISIAE;

EID: 0642371188     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200304030-00005     Document Type: Article

References (23)

1. Versicor Inc. Versicor Announces Positive Phase II Results With Anidulafungin for Invasive Candidiasis/Candidemia. Media Release: 6 Jan 2003. Available from: URL: http://www.versicor.com
2. Ponsler GD, McMillian CL. Tissue pharmacokinetics of LY303366 and radioactivity in male F344 rats following a single intravenous bolus dose of 5 mg/kg. Pharmaceutical Research 14 (Suppl.): 71, Nov 1997
3. Ni L, Smith B, Hatcher B, et al. Pharmacokinetics of LY303366 in healthy and HIV-infected volunteers after single-dose oral administration. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 489, 24 Sep 1998
4. Thye D, Kilfoil T, White RJ, et al. Anidulafungin: pharmacokinetics in subjects with mild and moderate hepatic impairment. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 6 (plus poster), 22 Sep 2001
5. Lucas R, Desante K, Hatcher B. LY303366 single dose pharmacokinetics and safety in healthy male volunteers. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy: 108, 15 Sep 1996
6. Vicuron Pharmaceuticals Inc. Vicuron Submits New Drug Application for Anidulafungin to FDA. Media Release: 28 Apr 2003. Available from: URL: http://www.versicor.com
7. Thye D, Shepherd B, White RJ, et al. Anidulafungin: a phase 1 study to identify the maximum tolerated dose in healthy volunteers. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 6 (plus poster), 22 Sep 2001
8. Versicor Inc. Versicor Announces Positive Phase III Clinical Trial Results With Anidulafungin for Esophageal Candidiasis. Media Release: 17 Mar 2003. Available from: URL: http:// www.versicor.com
9. Clemons KV, Sobel RA, Stevens DA. Toxicity of LY303366, an echinocandin antifungal, in mice pretreated with glucocorticoids. Antimicrobial Agents and Chemotherapy 44: 378-381, Feb 2000
10. White RJ, Thye D. Anidulafungin does not affect the metabolism of cyclosporin by human hepatic microsomes. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 6 (plus poster), 22 Sep 2001
11. Petraitiene R, Petraitis V, Groll AH. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrobial Agents and Chemotherapy 43: 2148-2155, Sep 1999
12. Zeckner D, Butler T, Boylan C. LY303366, activity in a rat mucocutaneous vaginal candidiasis model. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy: 252, 1994
13. Zeckner D, Butler T, Boylan C. LY303366, activity in a murine systemic candidiasis model. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 186, 1993
14. Zeckner D, Butler T, Boylan C. LY303366, activity against systemic aspergillosis and histoplasmosis in murine models. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 186, 1993
15. Verweij PE, Oakley KL, Morrissey J. Efficacy of LY303,366 against amphotericin B susceptible and resistant A. fumigatus infection in an immunocompromised murine model. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 158, 28 Sep 1997
16. Stevens DA. Drug interacvtion studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (nikkomycin Z) for inhibiton and killing of fungal pathogens. Antimicrobial Agents and Chemotherapy 44: 2547-2548, Sep 2000
17. Current WL, Boylan CJ, Raab PP. Anti-pneumocystis activity of LY303366 and other echinocandin B analogs. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 186, 1993
18. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. Journal of Clinical Microbiology 36: 2950-2956, Oct 1998
19. Pfaller MA, Marco F, Messer SA, et al. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagnostic Microbiology and Infectious Disease 30: 251-255, Apr 1998
20. Green LJ, Marder P, Mann LL. LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability. Antimicrobial Agents and Chemotherapy 43: 830-835, Apr 1999
21. Espinel-Ingroff A, Turik MA, Arevalo P. The in vitro inhibitory and fungicidal activities of the new echinocandin LY303366 against Candida albicans. Ninety-Ninth General Meeting American Society for Microbiology: 138, 30 May 1999
22. Chávez M, Bernal S, Valverde A, et al. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. Journal of Antimicrobial Chemotherapy 44: 697-700, Nov 1999
23. Cuenca-Estrella M, Mellado E, Diaz-Guerra TM, et al. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. Journal of Antimicrobial Chemotherapy 46: 475-477, Sep 2000